Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Amneal Pharmaceuticals, Inc. (AMRX) Going To Burn These Hedge Funds ?

Does Amneal Pharmaceuticals, Inc. (NYSE:AMRX) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend to generate millions in profits each year. It is also true that some hedge fund players fail inconceivably on some occasions, but net net their stock picks have been generating superior risk-adjusted returns on average over the years.

Is Amneal Pharmaceuticals, Inc. (NYSE:AMRX) a first-rate investment right now? The smart money is becoming more confident. The number of long hedge fund positions moved up by 2 in recent months. Our calculations also showed that AMRX isn’t among the 30 most popular stocks among hedge funds (view the video below).
5 Most Popular Stocks Among Hedge Funds
Video: Click the image to watch our video about the top 5 most popular hedge fund stocks.

In the financial world there are dozens of gauges stock traders have at their disposal to assess their stock investments. A pair of the most under-the-radar gauges are hedge fund and insider trading signals. We have shown that, historically, those who follow the best picks of the best investment managers can outpace the S&P 500 by a superb margin (see the details here).

SAC CAPITAL ADVISORS

Unlike former hedge manager, Dr. Steve Sjuggerud, who is convinced Dow will soar past 40000, our long-short investment strategy doesn’t rely on bull markets to deliver double digit returns. We only rely on hedge fund buy/sell signals. We’re going to take a peek at the recent hedge fund action encompassing Amneal Pharmaceuticals, Inc. (NYSE:AMRX).

What have hedge funds been doing with Amneal Pharmaceuticals, Inc. (NYSE:AMRX)?

At Q2’s end, a total of 10 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of 25% from one quarter earlier. On the other hand, there were a total of 13 hedge funds with a bullish position in AMRX a year ago. With hedge funds’ capital changing hands, there exists a few notable hedge fund managers who were increasing their stakes significantly (or already accumulated large positions).

No of Hedge Funds with AMRX Positions

Of the funds tracked by Insider Monkey, Point72 Asset Management, managed by Steve Cohen, holds the most valuable position in Amneal Pharmaceuticals, Inc. (NYSE:AMRX). Point72 Asset Management has a $23.8 million position in the stock, comprising 0.1% of its 13F portfolio. Sitting at the No. 2 spot is Millennium Management, led by Israel Englander, holding a $4.4 million position; the fund has less than 0.1%% of its 13F portfolio invested in the stock. Remaining hedge funds and institutional investors with similar optimism consist of Ken Griffin’s Citadel Investment Group, Anand Parekh’s Alyeska Investment Group and D. E. Shaw’s D E Shaw.

As aggregate interest increased, specific money managers were leading the bulls’ herd. Point72 Asset Management, managed by Steve Cohen, established the largest position in Amneal Pharmaceuticals, Inc. (NYSE:AMRX). Point72 Asset Management had $23.8 million invested in the company at the end of the quarter. Ken Griffin’s Citadel Investment Group also made a $4.1 million investment in the stock during the quarter. The following funds were also among the new AMRX investors: Ken Griffin’s Citadel Investment Group, Marc Majzner’s Clearline Capital, and Gavin Saitowitz and Cisco J. del Valle’s Springbok Capital.

Let’s now take a look at hedge fund activity in other stocks similar to Amneal Pharmaceuticals, Inc. (NYSE:AMRX). We will take a look at GreenSky, Inc. (NASDAQ:GSKY), Cal-Maine Foods Inc (NASDAQ:CALM), Euronav NV (NYSE:EURN), and Myriad Genetics, Inc. (NASDAQ:MYGN). This group of stocks’ market values resemble AMRX’s market value.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
GSKY 20 89452 5
CALM 16 182069 0
EURN 16 153669 5
MYGN 15 214253 -2
Average 16.75 159861 2

View table here if you experience formatting issues.

As you can see these stocks had an average of 16.75 hedge funds with bullish positions and the average amount invested in these stocks was $160 million. That figure was $37 million in AMRX’s case. GreenSky, Inc. (NASDAQ:GSKY) is the most popular stock in this table. On the other hand Myriad Genetics, Inc. (NASDAQ:MYGN) is the least popular one with only 15 bullish hedge fund positions. Compared to these stocks Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is even less popular than MYGN. Hedge funds dodged a bullet by taking a bearish stance towards AMRX. Our calculations showed that the top 20 most popular hedge fund stocks returned 24.4% in 2019 through September 30th and outperformed the S&P 500 ETF (SPY) by 4 percentage points. Unfortunately AMRX wasn’t nearly as popular as these 20 stocks (hedge fund sentiment was very bearish); AMRX investors were disappointed as the stock returned -59.6% during the third quarter and underperformed the market. If you are interested in investing in large cap stocks with huge upside potential, you should check out the top 20 most popular stocks among hedge funds as many of these stocks already outperformed the market so far in 2019.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.